UNCY - Unicycive Therapeutics, Inc.

QQQ $ 604.92 $ 3.94 (0.66 %)

DIA $ 461.73 $ 2.22 (0.48 %)

SPY $ 665.28 $ 3.75 (0.57 %)

TLT $ 91.09 $ -0.14 (-0.15 %)

GLD $ 391.28 $ -7.46 (-1.88 %)

Previous Close

$ 4.71

Open

$ 4.88

Bid

$ 4.63 x 100

Ask

$ 5.20 x 400

Day's Range

$ 4.69 - $ 5.18

52 Week Range

$ 3.71 - $ 11.00

Volume

199,471

Average Volume

Market Cap

57.94M

Beta (5Y Monthly)

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-14-2025	06-30-2025	10-Q
2	05-14-2025	03-31-2025	10-Q
3	03-31-2025	12-31-2024	10-K
4	11-13-2024	09-30-2024	10-Q
5	08-14-2024	06-30-2024	10-Q
6	05-13-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K
8	11-14-2023	09-30-2023	10-Q
9	08-14-2023	06-30-2023	10-Q
10	05-16-2023	03-31-2023	10-Q
11	03-31-2023	12-31-2022	10-K
12	11-14-2022	09-30-2022	10-Q
13	08-15-2022	06-30-2022	10-Q
14	05-12-2022	03-31-2022	10-Q
15	03-31-2022	12-31-2021	10-K
16	11-11-2021	09-30-2021	10-Q
17	08-16-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Benchmark Maintains Speculative Buy on Uni...
09/15/2025 12:57:49

Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the pric...

Unicycive Therapeutics Became Aware Of Se...
08/18/2025 20:25:06

-SEC Filing

Unicycive Therapeutics Receives US Patent ...
08/18/2025 11:12:59

Unicycive Therapeutics Q2 EPS $(0.52) Beat...
08/14/2025 11:16:59

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate o...

Unicycive Therapeutics Regains Nasdaq Comp...
07/08/2025 12:37:00

12 Health Care Stocks Moving In Monday's I...
06/30/2025 17:06:33

fda-raises-manufacturing-concerns-delays-unicycives-kidney-disease-drug-approval

FDA Raises Manufacturing Concerns, Delays ...
06/30/2025 14:58:21

FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ma...

12 Health Care Stocks Moving In Monday's P...
06/30/2025 12:08:07

Trading Halt: Halt status updated at 7:30:...
06/30/2025 11:30:04

The FDA Issues Complete Response Letter Fo...
06/30/2025 11:09:24

Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxyl...

Trading Halt: Halted at 7:00:00 a.m. ET - ...
06/30/2025 11:00:06

12 Health Care Stocks Moving In Wednesday'...
06/25/2025 21:06:05

Trading Halt: Halt status updated at 8:55:...
06/20/2025 12:55:04

Trading Halt: Halted at 7:50:00 p.m. ET - ...
06/18/2025 23:50:04

12 Health Care Stocks Moving In Tuesday's ...
06/17/2025 12:08:52

Unicycive Therapeutics Will Implement A 1-...
06/17/2025 11:03:27

12 Health Care Stocks Moving In Tuesday's ...
06/10/2025 17:06:51

unicycive-therapeutics-stock-is-trading-lower-tuesday-whats-going-on

Unicycive Therapeutics Stock Is Trading Lo...
06/10/2025 15:56:39

Unicycive announced update on its NDA for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney di...

12 Health Care Stocks Moving In Tuesday's ...
06/10/2025 12:09:16

Unicycive Provides Update On New Drug Appl...
06/10/2025 10:14:47